Study designs of evaluations included in the review
Randomised placebo-controlled, double-blind clinical trials (RCTs) of yohimbine with adequate statistical evaluation.
Specific interventions included in the review
Yohimbine (5 to 10 mg, 3 times per day) or yohimbine hydrochloride (5, 5.4 or 6 mg 3, 4, or 8 times per day) orally for a period of 2 to 10 weeks for the treatment groups and placebo for the control groups.
Participants included in the review
Men suffering some form of erectile dysfunction aged 18 to 70 years.
Outcomes assessed in the review
A decrease in erectile dysfunction, assessed by self-report by patient and partner, score on penile erectility and interest in sex, derogatis sexual functioning inventory, penile brachial index, daytime arousal test, Clinical Global Impression Scale, positive penile rigidity (by polysonography), inventory of sexual functioning, nocturnal penile tumescence, and waking erectile assessment.
How were decisions on the relevance of primary studies made?
All articles were evaluated independently by both authors.